The Challenge
A critical Phase III cardiovascular trial restart was placed at immediate risk when a previous supplier failed to deliver six essential standard-of-care (AxMP) medications across 17 clinical sites in Turkey.
With no room for delay, the consequences were significant: missed dosing windows, inactive sites, and further disruption to study timelines and costs. The sponsor required a partner capable of acting decisively within a complex local market.
The BAP Pharma Approach
BAP Pharma mobilised immediately, combining local market expertise with rapid decision-making to design a sourcing and on-demand distribution model in under one week.
Working through a trusted Turkish partner, the team secured all six required medications while streamlining requirements, including the removal of non-essential labelling steps to accelerate deployment.
Within 48–72 hours, all 17 sites were qualified and ready to receive product. A responsive supply model enabled temperature-controlled deliveries within 24–48 hours of request, supported by full documentation and end-to-end traceability.
The Outcome
BAP Pharma’s solution enabled the sponsor to quickly re-initiate enrolment and progress new site initiations without further supply disruption. Patient treatment remained on track, study momentum was restored, and the sponsor regained control of a highly time-critical trial phase.
By moving decisively and reducing supply risk at speed, BAP Pharma helped protect both patient access and the wider commercial investment behind the study.
By combining local market expertise with disciplined execution, we rapidly restored supply, protected study continuity and enabled the sponsor to regain control of a time-critical programme.
This project demonstrated the importance of making informed decisions quickly without compromising critical timelines, quality, or compliance. By simplifying the supply pathway, mobilising trusted local partnerships to procure high-pedigree products, and qualifying 17 clinical sites in record time, we minimised disruption and kept the trial moving forward.
